Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39537 | 0.83 | WDR5 (0.46) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL44280 | 0.83 | POLB (0.51) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL38543 | 0.80 | WDR5 (0.45) | HPGDMAPTRAB9APOLBWDR5 | |
| SCHEMBL11668836 | 0.78 | KDM4E (0.64) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL25263897 | 0.76 | KDM4E (0.65) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL38601 | 0.74 | KDM4E (0.49) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL44281 | 0.73 | KDM4E (0.48) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL25878920 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL1494696 | 0.73 | KDM4E (1.00) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL25876071 | 0.72 | KDM4E (0.73) | KDM4EALDH1A1HPGDLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | disclosed |
| WO-2011137587-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-10 | — | — | WO | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | KDM4E 1644/4885ALDH1A1 391/4885HPGD 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.